A pharmacometabonomic approach to predicting metabolic phenotypes and pharmacokinetic parameters of atorvastatin in healthy volunteers

Journal of Proteome Research

Volumn 14, Issue 9, 2015, Pages 3970-3981

  Huang, Qing ^a,b   Aa, Jiye ^a   Jia, Huning ^a,c   Xin, Xiaoqing ^a,c   Tao, Chunlei ^d   Liu, Linsheng ^e   Zou, Bingjie ^c   Song, Qinxin ^a   Shi, Jian ^a   Cao, Bei ^a   Yong, Yonghong ^f   Wang, Guangji ^a   Zhou, Guohua ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Institute for Food and Drug Control   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^d ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^e SOOCHOW UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

Author keywords

atorvastatin; metabolomics; personalized medicine; pharmacokinetics; pharmacometabonomics; precision medicine; prediction

Indexed keywords

2 OXOISOCAPROIC ACID; 3 HYDROXYPYRIDINE; ALANINE; ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; ATORVASTATIN; CHOLESTEROL; CITRIC ACID; GAMMA TOCOPHEROL; GLYCINE; HYDROXYBUTYRIC ACID; INOSITOL; INOSITOL PHOSPHATE; ISOLEUCINE; LEUCINE; LYSINE; MANNOSE; OCTANOIC ACID; TRYPTOPHAN; TYROSINE; VALINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; LEAST SQUARE ANALYSIS; METABOLISM; METABOLOMICS; PERSONALIZED MEDICINE; PROCEDURES; YOUNG ADULT;

ADULT; AREA UNDER CURVE; ATORVASTATIN CALCIUM; HEALTHY VOLUNTEERS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLOMICS; PRECISION MEDICINE; YOUNG ADULT;

EID: 84941049876     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/acs.jproteome.5b00440     Document Type: Article

References (71)

1. Evans, W. E.; Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response Annu. Rev. Genomics Hum. Genet. 2001, 2, 9-39 10.1146/annurev.genom.2.1.9
2. McLeod, H. L.; Evans, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy Annu. Rev. Pharmacol. Toxicol. 2001, 41, 101-21 10.1146/annurev.pharmtox.41.1.101
3. Garrison, L. P., Jr.; Carlson, R. J.; Carlson, J. J.; Kuszler, P. C.; Meckley, L. M.; Veenstra, D. L. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications Drug Metab. Rev. 2008, 40, 377-401 10.1080/03602530801952500
4. Wong, W. B.; Carlson, J. J.; Thariani, R.; Veenstra, D. L. Cost effectiveness of pharmacogenomics: a critical and systematic review PharmacoEconomics 2010, 28, 1001-13 10.2165/11537410-000000000-00000
5. Beaulieu, M.; de Denus, S.; Lachaine, J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests Pharmacogenomics 2010, 11, 1573-90 10.2217/pgs.10.145
6. Kitsios, G. D.; Kent, D. M. Personalised medicine: not just in our genes BMJ. 2012, 344, e2161 10.1136/bmj.e2161
7. Corona, G.; Rizzolio, F.; Giordano, A.; Toffoli, G. Pharmaco-metabolomics: an emerging aomicsa tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets J. Cell. Physiol. 2012, 227, 2827-31 10.1002/jcp.24003
8. Clayton, T. A.; Lindon, J. C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J. P.; Le Net, J. L.; Baker, D.; Walley, R. J.; Everett, J. R.; Nicholson, J. K. Pharmaco-metabonomic phenotyping and personalized drug treatment Nature 2006, 440, 1073-7 10.1038/nature04648
9. Bayet-Robert, M.; Morvan, D.; Chollet, P.; Barthomeuf, C. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses Breast Cancer Res. Treat. 2010, 120, 613-26 10.1007/s10549-009-0430-1
10. Li, H.; Ni, Y.; Su, M.; Qiu, Y.; Zhou, M.; Qiu, M.; Zhao, A.; Zhao, L.; Jia, W. Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats J. Proteome Res. 2007, 6, 1364-70 10.1021/pr060513q
11. Kwon, H. N.; Kim, M.; Wen, H.; Kang, S.; Yang, H. J.; Choi, M. J.; Lee, H. S.; Choi, D.; Park, I. S.; Suh, Y. J.; Hong, S. S.; Park, S. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach Kidney Int. 2011, 79, 529-37 10.1038/ki.2010.440
12. Coen, M.; Goldfain-Blanc, F.; Rolland-Valognes, G.; Walther, B.; Robertson, D. G.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Pharmacometabonomic investigation of dynamic metabolic phenotypes associated with variability in response to galactosamine hepatotoxicity J. Proteome Res. 2012, 11, 2427-40 10.1021/pr201161f
13. Cunningham, K.; Claus, S. P.; Lindon, J. C.; Holmes, E.; Everett, J. R.; Nicholson, J. K.; Coen, M. Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response J. Proteome Res. 2012, 11, 4630-42 10.1021/pr300430u
14. Clayton, T. A.; Baker, D.; Lindon, J. C.; Everett, J. R.; Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 14728-33 10.1073/pnas.0904489106
15. Winnike, J. H.; Li, Z.; Wright, F. A.; Macdonald, J. M.; O'Connell, T. M.; Watkins, P. B. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans Clin. Pharmacol. Ther. 2010, 88, 45-51 10.1038/clpt.2009.240
16. O'Connell, T. M.; Watkins, P. B. The application of metabonomics to predict drug-induced liver injury Clin. Pharmacol. Ther. 2010, 88, 394-9 10.1038/clpt.2010.151
17. Backshall, A.; Sharma, R.; Clarke, S. J.; Keun, H. C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine Clin. Cancer Res. 2011, 17, 3019-28 10.1158/1078-0432.CCR-10-2474
18. Kaddurah-Daouk, R.; Boyle, S. H.; Matson, W.; Sharma, S.; Matson, S.; Zhu, H.; Bogdanov, M. B.; Churchill, E.; Krishnan, R. R.; Rush, A. J.; Pickering, E.; Delnomdedieu, M. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept Transl. Psychiatry 2011, 1, e26 10.1038/tp.2011.22
19. Lewis, J. P.; Yerges-Armstrong, L. M.; Ellero-Simatos, S.; Georgiades, A.; Kaddurah-Daouk, R.; Hankemeier, T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy Clin. Pharmacol. Ther. 2013, 94, 570-3 10.1038/clpt.2013.153
20. Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 14187-8 10.1073/pnas.0907721106
21. Nicholson, J. K.; Everett, J. R.; Lindon, J. C. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy Expert Opin. Drug Metab. Toxicol. 2012, 8, 135-9 10.1517/17425255.2012.646987
22. Everett, J. R.; Loo, R. L.; Pullen, F. S. Pharmacometabonomics and personalized medicine Ann. Clin. Biochem. 2013, 50, 523 10.1177/0004563213497929
23. Nicholson, J. K.; Wilson, I. D.; Lindon, J. C. Pharmacometabonomics as an effector for personalized medicine Pharmacogenomics 2011, 12, 103-11 10.2217/pgs.10.157
24. Liu, L.; Cao, B.; Aa, J.; Zheng, T.; Shi, J.; Li, M.; Wang, X.; Zhao, C.; Xiao, W.; Yu, X.; Sun, R.; Gu, R.; Zhou, J.; Wu, L.; Hao, G.; Zhu, X.; Wang, G. Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum PLoS One 2012, 7, e43389 10.1371/journal.pone.0043389
25. Phapale, P. B.; Kim, S. D.; Lee, H. W.; Lim, M.; Kale, D. D.; Kim, Y. L.; Cho, J. H.; Hwang, D.; Yoon, Y. R. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus Clin. Pharmacol. Ther. 2010, 87, 426-36 10.1038/clpt.2009.296
26. Grundy, S. M.; Cleeman, J. I.; Bairey Merz, C. N.; Brewer, H. B., Jr.; Clark, L. T.; Hunninghake, D. B.; Pasternak, R. C.; Smith, S. C., Jr.; Stone, N. J. Coordinating Committee of the National Cholesterol Education, P., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J. Am. Coll. Cardiol. 2004, 44, 720-32 10.1016/j.jacc.2004.07.001
27. Colhoun, H. M.; Betteridge, D. J.; Durrington, P. N.; Hitman, G. A.; W Neil, H. A.; Livingstone, S. J.; Thomason, M. J.; Mackness, M. I.; Charlton-Menys, V.; Fuller, J. H. investigators, C., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004, 364, 685-96 10.1016/S0140-6736(04)16895-5
28. Sever, P. S.; Poulter, N. R.; Dahlof, B.; Wedel, H.; Collins, R.; Beevers, G.; Caulfield, M.; Kjeldsen, S. E.; Kristinsson, A.; McInnes, G. T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm(ASCOT-LLA) Diabetes Care 2005, 28, 1151-7 10.2337/diacare.28.5.1151
29. Shepherd, J.; Barter, P.; Carmena, R.; Deedwania, P.; Fruchart, J. C.; Haffner, S.; Hsia, J.; Breazna, A.; LaRosa, J.; Grundy, S.; Waters, D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 2006, 29, 1220-6 10.2337/dc05-2465
30. Cholesterol Treatment Trialists; Kearney, P. M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 2008, 371, 117-25 10.1016/S0140-6736(08)60104-X
31. Keskitalo, J. E.; Kurkinen, K. J.; Neuvonen, P. J.; Niemi, M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin Clin. Pharmacol. Ther. 2008, 84, 457-61 10.1038/clpt.2008.25
32. Lee, Y. J.; Lee, M. G.; Lim, L. A.; Jang, S. B.; Chung, J. Y. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects Int. J. Clin. Pharmacol. Ther. 2010, 48, 36-45 10.5414/CPP48036
33. Lau, Y. Y.; Huang, Y.; Frassetto, L.; Benet, L. Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin. Pharmacol. Ther. 2007, 81, 194-204 10.1038/sj.clpt.6100038
34. Keskitalo, J. E.; Zolk, O.; Fromm, M. F.; Kurkinen, K. J.; Neuvonen, P. J.; Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin Clin. Pharmacol. Ther. 2009, 86, 197-203 10.1038/clpt.2009.79
35. He, B. X.; Shi, L.; Qiu, J.; Zeng, X. H.; Zhao, S. J. The effect of CYP3A4∗1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease J. Clin. Pharmacol. 2014, 54, 462-7 10.1002/jcph.229
36. Shin, J.; Pauly, D. F.; Pacanowski, M. A.; Langaee, T.; Frye, R. F.; Johnson, J. A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin Pharmacotherapy 2011, 31, 942-50 10.1592/phco.31.10.942
37. Riedmaier, S.; Klein, K.; Hofmann, U.; Keskitalo, J. E.; Neuvonen, P. J.; Schwab, M.; Niemi, M.; Zanger, U. M. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin. Pharmacol. Ther. 2010, 87, 65-73 10.1038/clpt.2009.181
38. Romaine, S. P.; Bailey, K. M.; Hall, A. S.; Balmforth, A. J. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy Pharmacogenomics J. 2010, 10, 1-11 10.1038/tpj.2009.54
39. Law, M. R.; Wald, N. J.; Rudnicka, A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ. 2003, 326, 1423 10.1136/bmj.326.7404.1423
40. Hoenig, M. R.; Walker, P. J.; Gurnsey, C.; Beadle, K.; Johnson, L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort J. Clin. Lipidol. 2011, 5, 91-6 10.1016/j.jacl.2011.01.001
41. Becker, M. L.; Visser, L. E.; van Schaik, R. H.; Hofman, A.; Uitterlinden, A. G.; Stricker, B. H. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy Pharmacoepidemiol. Drug Saf. 2010, 19, 75-81 10.1002/pds.1866
42. Wilke, R. A.; Moore, J. H.; Burmester, J. K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage Pharmacogenet. Genomics 2005, 15, 415-21 10.1097/01213011-200506000-00007
43. Harper, C. R.; Jacobson, T. A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr. Opin. Lipidol. 2007, 18, 401-8 10.1097/MOL.0b013e32825a6773
44. Joy, T. R.; Hegele, R. A. Narrative review: statin-related myopathy Ann. Intern. Med. 2009, 150, 858-68 10.7326/0003-4819-150-12-200906160-00009
45. Niemi, M. Transporter pharmacogenetics and statin toxicity Clin. Pharmacol. Ther. 2010, 87, 130-3 10.1038/clpt.2009.197
46. DeGorter, M. K.; Tirona, R. G.; Schwarz, U. I.; Choi, Y. H.; Dresser, G. K.; Suskin, N.; Myers, K.; Zou, G.; Iwuchukwu, O.; Wei, W. Q.; Wilke, R. A.; Hegele, R. A.; Kim, R. B. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care Circ.: Cardiovasc. Genet. 2013, 6, 400-8 10.1161/CIRCGENETICS.113.000099
47. Niemi, M.; Pasanen, M. K.; Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol Rev. 2011, 63, 157-81 10.1124/pr.110.002857
48. Group, S. C.; Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy - a genomewide study N. Engl. J. Med. 2008, 359, 789-99 10.1056/NEJMoa0801936
49. Feng, Q.; Wilke, R. A.; Baye, T. M. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions Pharmacogenomics 2012, 13, 579-94 10.2217/pgs.12.11
50. Talameh, J. A.; Kitzmiller, J. P. Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants J. Pharmacogenomics Pharmacoproteomics 2014, 5, 128 10.4172/2153-0645.1000128
51. Ni, X.; Zhang, W.; Huang, R. S. Pharmacogenomics discovery and implementation in genome-wide association studies era Wiley Interdiscip Rev. Syst. Biol. Med. 2013, 5, 1-9 10.1002/wsbm.1199
52. Gibson, D. M.; Bron, N. J.; Richens, A.; Hounslow, N. J.; Sedman, A. J.; Whitfield, L. R. Effect of age and gender on pharmacokinetics of atorvastatin in humans J. Clin. Pharmacol. 1996, 36, 242-6 10.1002/j.1552-4604.1996.tb04194.x
53. He, Y. J.; Zhang, W.; Chen, Y.; Guo, D.; Tu, J. H.; Xu, L. Y.; Tan, Z. R.; Chen, B. L.; Li, Z.; Zhou, G.; Yu, B. N.; Kirchheiner, J.; Zhou, H. H. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T > C polymorphism Clin. Chim. Acta 2009, 405, 49-52 10.1016/j.cca.2009.04.003
54. A, J.; Huang, Q.; Wang, G.; Zha, W.; Yan, B.; Ren, H.; Gu, S.; Zhang, Y.; Zhang, Q.; Shao, F.; Sheng, L.; Sun, J. Global analysis of metabolites in rat and human urine based on gas chromatography/time-of-flight mass spectrometry Anal. Biochem. 2008, 379, 20-6 10.1016/j.ab.2008.04.025
55. A, J.; Trygg, J.; Gullberg, J.; Johansson, A. I.; Jonsson, P.; Antti, H.; Marklund, S. L.; Moritz, T. Extraction and GC/MS analysis of the human blood plasma metabolome Anal. Chem. 2005, 77, 8086-94 10.1021/ac051211v
56. Trygg, J.; Holmes, E.; Lundstedt, T. Chemometrics in metabonomics J. Proteome Res. 2007, 6, 469-79 10.1021/pr060594q
57. Pasanen, M. K.; Fredrikson, H.; Neuvonen, P. J.; Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin. Pharmacol. Ther. 2007, 82, 726-33 10.1038/sj.clpt.6100220
58. Suhre, K.; Shin, S. Y.; Petersen, A. K.; Mohney, R. P.; Meredith, D.; Wagele, B.; Altmaier, E.; CARDIoGRAM; Deloukas, P.; Erdmann, J.; Grundberg, E.; Hammond, C. J.; de Angelis, M. H.; Kastenmuller, G.; Kottgen, A.; Kronenberg, F.; Mangino, M.; Meisinger, C.; Meitinger, T.; Mewes, H. W.; Milburn, M. V.; Prehn, C.; Raffler, J.; Ried, J. S.; Romisch-Margl, W.; Samani, N. J.; Small, K. S.; Wichmann, H. E.; Zhai, G.; Illig, T.; Spector, T. D.; Adamski, J.; Soranzo, N.; Gieger, C. Human metabolic individuality in biomedical and pharmaceutical research Nature 2011, 477, 54-60 10.1038/nature10354
59. Rhee, E. P.; Ho, J. E.; Chen, M. H.; Shen, D.; Cheng, S.; Larson, M. G.; Ghorbani, A.; Shi, X.; Helenius, I. T.; O'Donnell, C. J.; Souza, A. L.; Deik, A.; Pierce, K. A.; Bullock, K.; Walford, G. A.; Vasan, R. S.; Florez, J. C.; Clish, C.; Yeh, J. R.; Wang, T. J.; Gerszten, R. E. A genome-wide association study of the human metabolome in a community-based cohort Cell Metab. 2013, 18, 130-43 10.1016/j.cmet.2013.06.013
60. Kettunen, J.; Tukiainen, T.; Sarin, A. P.; Ortega-Alonso, A.; Tikkanen, E.; Lyytikainen, L. P.; Kangas, A. J.; Soininen, P.; Wurtz, P.; Silander, K.; Dick, D. M.; Rose, R. J.; Savolainen, M. J.; Viikari, J.; Kahonen, M.; Lehtimaki, T.; Pietilainen, K. H.; Inouye, M.; McCarthy, M. I.; Jula, A.; Eriksson, J.; Raitakari, O. T.; Salomaa, V.; Kaprio, J.; Jarvelin, M. R.; Peltonen, L.; Perola, M.; Freimer, N. B.; Ala-Korpela, M.; Palotie, A.; Ripatti, S. Genome-wide association study identifies multiple loci influencing human serum metabolite levels Nat. Genet. 2012, 44, 269-76 10.1038/ng.1073
61. Morris, M. E.; Felmlee, M. A. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid AAPS J. 2008, 10, 311-21 10.1208/s12248-008-9035-6
62. Goto, Y.; Itagaki, S.; Umeda, S.; Kobayashi, M.; Hirano, T.; Iseki, K.; Tadano, K. Transepithelial transport of telmisartan in caco-2 monolayers Biol. Pharm. Bull. 2005, 28, 2235-9 10.1248/bpb.28.2235
63. Wu, X.; Whitfield, L. R.; Stewart, B. H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter Pharm. Res. 2000, 17, 209-15 10.1023/A:1007525616017
64. Pasanen, M. K.; Miettinen, T. A.; Gylling, H.; Neuvonen, P. J.; Niemi, M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate Pharmacogenet. Genomics 2008, 18, 921-6 10.1097/FPC.0b013e32830c1b5f
65. Xiang, X.; Han, Y.; Neuvonen, M.; Pasanen, M. K.; Kalliokoski, A.; Backman, J. T.; Laitila, J.; Neuvonen, P. J.; Niemi, M. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans Pharmacogenet. Genomics 2009, 19, 447-57 10.1097/FPC.0b013e32832bcf7b
66. Kaddurah-Daouk, R.; Baillie, R. A.; Zhu, H.; Zeng, Z. B.; Wiest, M. M.; Nguyen, U. T.; Wojnoonski, K.; Watkins, S. M.; Trupp, M.; Krauss, R. M. Enteric microbiome metabolites correlate with response to simvastatin treatment PLoS One 2011, 6, e25482 10.1371/journal.pone.0025482
67. Xiang, X.; Backman, J. T.; Neuvonen, P. J.; Niemi, M. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings Basic Clin. Pharmacol. Toxicol. 2012, 110, 245-52 10.1111/j.1742-7843.2011.00792.x
68. Kaddurah-Daouk, R.; Baillie, R. A.; Zhu, H.; Zeng, Z. B.; Wiest, M. M.; Nguyen, U. T.; Watkins, S. M.; Krauss, R. M. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study Metabolomics 2010, 6, 191-201 10.1007/s11306-010-0207-x
69. Trupp, M.; Zhu, H.; Wikoff, W. R.; Baillie, R. A.; Zeng, Z. B.; Karp, P. D.; Fiehn, O.; Krauss, R. M.; Kaddurah-Daouk, R. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment PLoS One 2012, 7, e38386 10.1371/journal.pone.0038386
70. Kokudai, M.; Inui, N.; Takeuchi, K.; Sakaeda, T.; Kagawa, Y.; Watanabe, H. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers J. Clin. Pharmacol. 2009, 49, 568-73 10.1177/0091270009332435
71. Lins, R. L.; Matthys, K. E.; Verpooten, G. A.; Peeters, P. C.; Dratwa, M.; Stolear, J. C.; Lameire, N. H. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrol., Dial., Transplant. 2003, 18, 967-76 10.1093/ndt/gfg048